Incannex Healthcare Limited (NASDAQ: IXHL) (ASX: IHL), an Australian cannabinoid and psychedelic medicine developer, has appointed Eurofins Scientific SE (EPA: ERF) to manufacture two medicated chewing gum products for treating nicotine and opioid addiction disorders.
Incannex announced the news on Friday, and the development follows a series of granted patents and patent applications for the two drugs that were transferred to the company in August from APIRx Pharmaceuticals following its acquisition by the Australian drug developer.
Eurofins will be undertaking the development, formulation and production of the CannQuit-N and CannQuit-O products which utilize CBD to help diminish anxiety and cravings in consumers.
CannQuit-N has a combination of CBD and nicotine while CannQuit-O utilizes the cannabinoid and an “off-patent prescription opioid antagonist” which helps prevent dependency on the drug through its effect on receptors in the brain.
The products now being manufactured by Eurofins will be cGMP certified and used in clinical trials to assess their safety and efficacy prior to filing investigational new drug (IND) and new drug applications (NDA) with the FDA before eventual commercialization.
“Opioid and nicotine addiction are significant health problems and a major burden on health systems throughout the world. CannQuit products are designed to improve established therapies for the treatment of addiction. They do this by adding CBD, which is known to reduce cravings and anxiety which is critical for breaking the addiction cycle,” said Mark Bleackley, Chief Scientific Officer of Incannex.
Bleackley added that the products have strong potential to improve treatment outcomes for those who suffer from nicotine and opioid use disorders and that the company was excited to test the chewables in clinical trials following manufacture by Eurofins.